co.don AG Logo

co.don AG

Develops personalized cartilage cell transplants for minimally invasive joint repair.

CNW | F

Overview

Corporate Details

ISIN(s):
DE000A3E5C08 (+1 more)
LEI:
3912006R73YW0SX1KG21
Country:
Germany
Address:
Warthestr. 21, 14513 Teltow
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

co.don AG is a biopharmaceutical company specializing in tissue engineering and regenerative medicine. The company focuses on the development, manufacturing, and marketing of autologous cell therapies for the treatment of articular cartilage defects. Its core process involves using a patient's own cartilage cells (chondrocytes) to produce personalized cell transplants, such as spherical cartilage cell implants (spheroids), for the minimally invasive repair of joints. Following an asset purchase in early 2023, the operative business was taken over by an investor and now operates as CO.DON GmbH, a ReLive company, continuing its work in human cell-based therapies.

Social Media

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2022-09-30 00:00
Interim Report
Halbjahresfinanzbericht nach WpHG zum Geschäftsjahr vom 01.01.2022 bis zum 30.0…
German 142.4 KB
2022-09-29 00:00
Report Publication Announcement
Hinweis auf Halbjahresfinanzbericht vom 01.01.2022 bis zum 30.06.2022
German 6.4 KB
2022-07-11 00:00
Regulatory News Service
Jahres- und Konzernabschluss zum Geschäftsjahr vom 01.01.2021 bis zum 31.12.2021
German 1.3 MB
2022-07-06 00:00
Report Publication Announcement
Berichtigung der Veröffentlichung vom 14.06.2022
German 6.4 KB
2022-06-14 00:00
Report Publication Announcement
Berichtigt am 06.07.2022
German 6.4 KB
2022-04-29 00:00
Report Publication Announcement
Hinweis auf Jahresfinanzbericht vom 01.01.2021 bis zum 31.12.2021
German 6.4 KB
2021-09-11 00:00
Director's Dealing
CO.DON AG: Mitteilung über Eigengeschäfte von Führungskräften gem. Art. 19 MAR
German 13.9 KB
2021-08-30 00:00
Interim Report
Halbjahresfinanzbericht
German 148.6 KB
2021-05-27 00:00
Report Publication Announcement
Jahresabschluss zum Geschäftsjahr vom 01.01.2020 bis zum 31.12.2020
German 4.2 KB
2021-05-25 00:00
Annual Report
Konzernabschluss zum Geschäftsjahr vom 01.01.2020 bis zum 31.12.2020
German 4.2 KB
2021-05-22 00:00
Regulatory News Service
Ad-hoc-Meldung gemäß Art. 17 MAR in Verbindung mit § 4 Abs. 1 S. 1 Nr. 1a WpAV
English 11.8 KB
2020-08-28 00:00
Interim Report
Datum:28.08.2020
German 381.2 KB
2020-08-24 00:00
Report Publication Announcement
Datum:24.08.2020
German 12.2 KB
2020-07-28 00:00
Annual Report
Datum:28.07.2020
German 998.8 KB
2020-07-07 00:00
Annual Report
Datum:07.07.2020
German 41.3 KB

Automate Your Workflow. Get a real-time feed of all co.don AG filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for co.don AG

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for co.don AG via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
2021-10-21 Günther, Bernd Supervisory board Buy None 35.84 EUR
2021-10-20 Laik, Robin Board Other None 10,348,300.00 EUR
2021-10-20 ELBER GmbH Close relation Other None 10,179,000.00 EUR
2021-10-20 Rofalski, Volker Supervisory board Other None 292,500.00 EUR
2021-10-20 Müller, Dr. Axel Supervisory board Other None 195,000.00 EUR
2021-10-20 Laumann, Johannes Board Other None 131,625.00 EUR
2021-10-20 Laik, Louisa Close relation Other None 129,987.00 EUR
2021-10-20 Laik, Daniel Close relation Other None 97,500.00 EUR
2021-10-20 Friedrich, Neela Close relation Other None 64,993.50 EUR
2021-10-20 Schleede, Dr. Kristian Board Other None 29,250.00 EUR

Peer Companies

IN8BIO, INC. Logo
Clinical-stage biopharma developing gamma-delta T cell therapies for solid & hematological tumors.
United States of America
INAB
Develops targeted dermatology & oncology therapies using unique formulation & delivery technologies.
United Kingdom
INC
INCYTE CORP Logo
Develops proprietary therapeutics for serious unmet needs in oncology and inflammation.
United States of America
INCY
Indaptus Therapeutics, Inc. Logo
Develops immunotherapies using engineered bacteria to treat cancer and viral infections.
United States of America
INDP
Indivior PLC Logo
Develops pharmaceuticals for opioid use disorder, addiction, and serious mental illnesses.
United Kingdom
INDV
Infant Bacterial Therapeutics Logo
Develops live bacterial medicines to prevent rare, severe gut diseases in premature infants.
Sweden
IBT
InflaRx N.V. Logo
Develops complement system inhibitors for severe inflammatory diseases and immuno-dermatology.
United States of America
IFRX
Inhibikase Therapeutics, Inc. Logo
Develops kinase inhibitors to treat neurodegenerative diseases like Parkinson's.
United States of America
IKT
Inhibrx Biosciences, Inc. Logo
Clinical-stage biopharma developing novel biologic therapies for life-threatening cancers.
United States of America
INBX
InMed Pharmaceuticals Inc. Logo
Develops cannabinoid drugs for unmet medical needs and supplies rare cannabinoids for B2B wellness.
United States of America
INM

Talk to a Data Expert

Have a question? We'll get back to you promptly.